HAMILTON, ON and BOSTON, Aug. 29, 2022 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as ...
First-in-Human Study of OBI-999, a Globo H-Targeting Antibody-Drug Conjugate, in Patients With Advanced Solid Tumors Eighty-five larotrectinib patients and 28 non-TRK-inhibitor SoC patients were ...
HAMILTON, ON and BOSTON, March 20, 2023 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as ...
Patients with diabetes, obesity, rheumatoid arthritis, or coronary artery disease have a higher risk of UTIs post-spinal fusion for deformities. The study focused on posterior fusion procedures, ...
BOULDER, Colo., Nov. 3, 2025 /PRNewswire/ -- Enliven Therapeutics, Inc. (ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, ...
COVALENT-101 now includes patients with relapsed/refractory (R/R) CLL BMF-219 is the first menin inhibitor in the clinic for CLL Preclinical data presented at ASCO 2022 demonstrated the potency of BMF ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback